Cumulative response rates in patients with or without a BCR-ABL mutation who received dasatinib treatment at any dose or 100 mg once daily (QD) after resistance or suboptimal response to imatinib. CHR indicates complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; and MMR, major molecular response.